The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
OXLUMO (Medison Pharma Australia Pty Ltd)
Product name
OXLUMO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
154 (175 working days)
Active ingredients
lumasiran sodium
Registration type
NCE/NBE
Indication
Oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (PH1) in all agegroups.